TY - JOUR
T1 - Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs)
T2 - An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
AU - Sciot, Raf
AU - Debiec-Rychter, Maria
AU - Daugaard, Soren
AU - Fisher, Cyril
AU - Collin, Francoise
AU - Glabbeke, Martine van
AU - Verweij, Jaap
AU - Blay, Jean Yves
AU - Hogendoorn, Pancras C.W.
PY - 2008/9
Y1 - 2008/9
N2 - Rationale: The 62005 EORTC phase III trial, comparing two doses of imatinib in patients with advanced GIST, reported a median progression-free survival of 25 months with a trend towards dose dependency for progression-free survival. The current analysis of that study aimed to assess whether histological/immunohistochemical parameters correlate with clinical response to imatinib. Patients and methods: Pre-treatment samples of GISTs from 546 patients enroled in phase III study were analysed for immunohistochemical characteristics, correlations with clinicopathological data, with survival and with tumours' genotype. Results: There was no correlation between immunomorphological or clinical characteristics and response to treatment, PFS or OS. No correlations between immunophenotype of the tumour and PFS or OS in the two dose arms were observed. Conclusions: The results confirm the heterogeneity of GIST in terms of immunophenotypic expression, but indicate that these parameters have no impact on the outcome of the patients under imatinib treatment.
AB - Rationale: The 62005 EORTC phase III trial, comparing two doses of imatinib in patients with advanced GIST, reported a median progression-free survival of 25 months with a trend towards dose dependency for progression-free survival. The current analysis of that study aimed to assess whether histological/immunohistochemical parameters correlate with clinical response to imatinib. Patients and methods: Pre-treatment samples of GISTs from 546 patients enroled in phase III study were analysed for immunohistochemical characteristics, correlations with clinicopathological data, with survival and with tumours' genotype. Results: There was no correlation between immunomorphological or clinical characteristics and response to treatment, PFS or OS. No correlations between immunophenotype of the tumour and PFS or OS in the two dose arms were observed. Conclusions: The results confirm the heterogeneity of GIST in terms of immunophenotypic expression, but indicate that these parameters have no impact on the outcome of the patients under imatinib treatment.
KW - Clinical trials
KW - Gastrointestinal stromal tumour
KW - Immunohistochemistry
KW - Mutational analysis
KW - Pathology
KW - Prognoses
KW - Soft tissue tumours
UR - http://www.scopus.com/inward/record.url?scp=49549113809&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2008.06.003
DO - 10.1016/j.ejca.2008.06.003
M3 - Article
C2 - 18653326
AN - SCOPUS:49549113809
SN - 0959-8049
VL - 44
SP - 1855
EP - 1860
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 13
ER -